Telomir Pharmaceuticals, Inc.
TELO· Nasdaq
TELOTelomir Pharmaceuticals, Inc.
Filed Aug 13, 2024 · 10-Q · 44 days after period end · 0001493152-24-031606
| Metric | Q2 2024 | Q2 2023 |
|---|---|---|
| Net Income | -$1.39M | -$1.55M |
| EPS Diluted | $0.05 | -$0.06 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Telomir Pharmaceuticals, Inc. · CIK 1971532 · Engraved from SEC EDGAR
ended Jun 30, 2024 · filed Aug 13, 2024 · 44 d after period end
